Why doesn't mc-1 seem like an undervalued asset, in your opinion. The first 30 days after cabg surgery has about a 15 percent risk of heart attack or death.
The phase two trial reduced that risk but 40 percent. There is no approved drug for that indication. It would be at least a 500 million dollar opportunity in the US and about equal that size in Europe. The nearest competitiors are in phase 1 trials.
They only have to get aggrastat to about 30 million by taking share from integrilin and reopro. With a sales force concentrating on docs that haven't been seen for several years that shouldn't be impossible.
Market Data 
Markets 
AI
